M&A Could Give Biotech Stocks a Boost in 2017
Here are some questions, thoughts, declarations, catalysts and observations about biotech stocks in 2017 from TheStreet's Adam Feuerstein.
Investors and analysts expect mergers and acquisitions to be the most important tailwind for biotech stock outperformance in 2017. Fund flows with biotech have picked up after the election in November and the trend could continue into 2017. There has been talks of increasing drug prices, which was a huge overhang for biotech and pharma stocks in 2016. With Trump as President-elect there is no saying what will happen in the future with biotech and drug stocks.
This article was written by a staff member of TheStreet.
